Abstract: A mouthguard able to be shaped in the mouth, has an adaptable structure consisting of an adaptable material, and a skeleton, at least partially covered by the adaptable structure, consisting of a non-adaptable material. The mouthguard also has a removable pallet consisting of a non-adaptable material and comprising a first region intended to butt against the skeleton, the region of the pallet being dimensioned such that, during the adaptation phase of the mouthguard, the combined presence of the pallet and of the skeleton ensures both ventilation space and the presence of sufficient material at the incisor-canine area.

Abstract: The invention pertains to a cyclic peptide comprising the following sequence: -S1-X1-S2-X2- wherein S1 is a first target peptide sequence of a protease enzyme E1, S2 is a second target peptide sequence of a protease enzyme E2, S1 and S2 possibly being the same or different, said first peptide sequence S1 and said second peptide sequence S2 comprising 4 to 14 amino acids, E1 and E2 possibly corresponding to the same protease enzyme or to two different protease enzymes, X1 is a probe carrying a fluorescent donor group and X2 is a probe carrying a fluorescent or non-fluorescent acceptor group. Application of these peptides to determination of the activity of protease enzymes.

Abstract: The disclosure relates to a novel use of a food composition for human use, having fewer than 1600 picomoles of polyamines, for the production of a medical food which is intended to combat a syndrome or pathology involving N-methyl-D-aspartate receptor subunit NR2-B.

Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.

Abstract: Novel compounds which are alkaloids related to bis [O-(14-Benzoylaconine-8-YL)]esters.

Abstract: A mouthguard able to be shaped in the mouth, has an adaptable structure consisting of an adaptable material, and a skeleton, at least partially covered by the adaptable structure, consisting of a non-adaptable material. The mouthguard also has a removable pallet consisting of a non-adaptable material and comprising a first region intended to butt against the skeleton, the region of the pallet being dimensioned such that, during the adaption phase of the mouthguard, the combined presence of the pallet and of the skeleton ensures both ventilation space and the presence of sufficient material at the incisor-canine area.

Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Abstract: The invention concerns a system capable of generating a magnetic indication B0 comprising gradients (Gx, Gy, Gz) in certain directions, transmitting ratio frequency wave pulse sequences (RF) perpendicular to B0 in a range of adjustable frequencies, and detecting electromagnetic signals received from a body part (4). The method includes injecting a contrast product in said body part, capable of being temporarily fixed in an observed zone (1), and comprising an element capable of causing chemical displacement of a resonance frequency of water hydrogen protons; exciting said body part, using a radio wave pulse sequence; in a range of frequencies adjusted on the basis of the magnetic induction B0 and the chemical displacement for some of said waves; detecting the electromagnetic signals received in said body part, substantially corresponding to the magnetic resonance signals of the protons of the observed zone having undergone the chemical displacement.

Abstract: Modified yeast cells comprising at least one mutation of the tryptophan 136 (W136), leucine 183 (L183), or leucine 247 (L247) codon of the mitochondrial ATP6 gene, responsible for NARP syndrome in humans and uses thereof for screening for medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as NARP syndrome.

Abstract: The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the ade1-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates.

Abstract: The invention relates to an industrial method for producing an interest heterologous RNA and to a system for carrying out said production method consisting (1) in transforming mitochondrions of yeast cells free of mitochondrial RNA with a mitochondrial transcription vector comprising at least one copy of the DNA encoding said interest heterologous RNA which are controlled by regulatory element(s) of the mitochondrial transcription and a reporter gene thereof or a fragment of said reporter gene, 2) identifying yeast transformants by incorporating the interest DNA into the mitochondrions thereof, (3) culturing the yeast mitochondrial transformants selected at the stage (2), (4) isolating the mitochondrions from the yeast mitochondrial transformants obtainable at stages (3) and in extracting and purifying the interest heterologous RNA from said mitochondrions.

Abstract: The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates.

Abstract: The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.

Abstract: A method for determining if an individual is infected by Mycoplasma pneumonia, including, determining if antibodies directed against a protein comprising SEQ ID NO: 2 are present in a biological sample of the individual, and deducing therefrom that the individual is infected by Mycoplasma pneumoniae.

Abstract: A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and pharmaceutical compositions having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy.

Abstract: The present invention concerns a simple RNA strand, which includes, from extremity 3? to extremity 5?, (i) a sequence of complementary nucleic acid to the non-coding region 5? (5?UTR) of the genomic RNA (strand (+)) of the hepatitis C virus (VHC) or another RNA virus replicating thanks to an RNA dependent RNA polymerase, the nucleic acid sequence of which allows the replication of said simple RNA strand molecule by the replication complex of said virus, (ii) the complementary nucleic acid sequence of a corresponding nucleic acid sequence from the site of internal entry of the ribosome (1RES), and (iii) the complementary nucleic acid sequence of a suicide gene or a coding gene for a protein interfering with the replication of the VHC virus or another RNA virus replicating thanks to an RNA dependent RNA polymerase; an ADN molecule allowing the transcription of said simple RNA strand molecule; a vector of nucleic acids including said molecules of nucleic acids; and a pharmaceutical compound including said molecu

Abstract: The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Abstract: A method for determining if an individual is infected by Mycoplasma pneumonia, including, determining if antibodies directed against a protein comprising SEQ ID NO: 2 are present in a biological sample of the individual, and deducing therefrom that the individual is infected by Mycoplasma pneumoniae.

Abstract: Modified yeast cells comprising at least one mutation of the tryptophan 136 (W136), leucine 183 (L183), or leucine 247 (L247) codon of the mitochondrial ATP6 gene, responsible for NARP syndrome in humans and uses thereof for screening for medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as NARP syndrome.